PH12014500596A1 - Plant steroids and uses thereof - Google Patents

Plant steroids and uses thereof

Info

Publication number
PH12014500596A1
PH12014500596A1 PH1/2014/500596A PH12014500596A PH12014500596A1 PH 12014500596 A1 PH12014500596 A1 PH 12014500596A1 PH 12014500596 A PH12014500596 A PH 12014500596A PH 12014500596 A1 PH12014500596 A1 PH 12014500596A1
Authority
PH
Philippines
Prior art keywords
intestinal
drug
diseases
drug conjugate
relates
Prior art date
Application number
PH1/2014/500596A
Other languages
English (en)
Inventor
John F Arnett
Michael Davidson
Sadik Elshani
Roelof Rongen
Original Assignee
Davidson Lopez Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Davidson Lopez Llc filed Critical Davidson Lopez Llc
Publication of PH12014500596A1 publication Critical patent/PH12014500596A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2014/500596A 2011-09-16 2012-09-14 Plant steroids and uses thereof PH12014500596A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535661P 2011-09-16 2011-09-16
US201261675966P 2012-07-26 2012-07-26
PCT/US2012/055549 WO2013040441A1 (en) 2011-09-16 2012-09-14 Plant steroids and uses thereof

Publications (1)

Publication Number Publication Date
PH12014500596A1 true PH12014500596A1 (en) 2014-04-21

Family

ID=47883793

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2014/500596A PH12014500596A1 (en) 2011-09-16 2012-09-14 Plant steroids and uses thereof

Country Status (16)

Country Link
US (2) US10086082B2 (https=)
EP (1) EP2755660B1 (https=)
JP (2) JP6035338B2 (https=)
KR (1) KR20140093661A (https=)
CN (2) CN103987390A (https=)
AU (1) AU2012308332A1 (https=)
BR (1) BR112014006222A2 (https=)
CA (1) CA2848979C (https=)
EA (1) EA201490637A1 (https=)
HK (1) HK1200358A1 (https=)
IL (1) IL231541A0 (https=)
IN (1) IN2014CN02688A (https=)
MX (1) MX2014003260A (https=)
PH (1) PH12014500596A1 (https=)
SG (1) SG11201400652UA (https=)
WO (1) WO2013040441A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015021388A2 (pt) 2013-03-08 2017-07-18 Allergan Inc conjugados esteroides de ciclosporina a
RU2015138891A (ru) 2013-03-08 2017-04-11 Аллерган, Инк. Конъюгаты антибиотиков, напрямую связанные со стероидными препаратами
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
EP4537847A3 (en) 2017-01-13 2025-07-30 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR102139678B1 (ko) * 2017-11-24 2020-07-31 전북대학교 산학협력단 N-아세틸 또는 n-아실 아미노산을 포함하는 아토피 또는 가려움증 치료용 조성물
CN110051674A (zh) * 2018-07-26 2019-07-26 中国人民解放军空军军医大学第一附属医院 豆甾醇在制备治疗胃癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052029A1 (en) 1999-03-04 2000-09-08 Eugene Science Inc. Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same
EP1189924B1 (en) * 1999-06-23 2004-08-18 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AU2002252387A1 (en) * 2001-03-14 2002-09-24 Lipogenics, Inc. Novel anti-inflammatory compositions and methods of use
EP1385530A4 (en) 2001-05-09 2005-11-09 Mediplex Corp FORMULATION OF AMPHIPHILENE HEPARIN DERIVATIVES FOR IMPROVING SLIME SKIN ABSORPTION
SE0103765D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab New use
US20040236125A1 (en) * 2002-09-25 2004-11-25 Forbes Medi-Tech Inc. Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation
WO2004095926A2 (en) 2003-04-28 2004-11-11 Monsanto Technology, Llc Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield
US20050234025A1 (en) * 2004-04-20 2005-10-20 Forbes Medi-Tech Inc. Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
WO2006099445A2 (en) * 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
AU2007299705B2 (en) * 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
JP2010509355A (ja) * 2006-11-06 2010-03-25 ジャイナ ファーマシューティカルズ,インコーポレーテッド グッグルリン脂質の方法および組成物
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2011109472A1 (en) 2010-03-02 2011-09-09 Imagenetix, Inc. Compositions comprising myristic acid and uses thereof

Also Published As

Publication number Publication date
US20150141390A1 (en) 2015-05-21
IN2014CN02688A (https=) 2015-07-03
SG11201400652UA (en) 2014-09-26
CN103987390A (zh) 2014-08-13
JP2014526515A (ja) 2014-10-06
JP6035338B2 (ja) 2016-11-30
CA2848979A1 (en) 2013-03-21
EA201490637A1 (ru) 2014-11-28
CA2848979C (en) 2019-11-05
EP2755660A1 (en) 2014-07-23
US10086082B2 (en) 2018-10-02
IL231541A0 (en) 2014-04-30
AU2012308332A1 (en) 2014-04-10
MX2014003260A (es) 2014-09-08
EP2755660A4 (en) 2015-03-18
KR20140093661A (ko) 2014-07-28
CN109384825A (zh) 2019-02-26
BR112014006222A2 (pt) 2017-04-11
JP2017019871A (ja) 2017-01-26
EP2755660B1 (en) 2019-11-06
HK1200358A1 (en) 2015-08-07
US20190083632A1 (en) 2019-03-21
WO2013040441A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
PH12014500596A1 (en) Plant steroids and uses thereof
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MX348003B (es) Metodos y medios para modificar un genoma vegetal.
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
AU2011328009A8 (en) Compounds and methods for treating pain
HK1216850A1 (zh) 抗ntb-a抗體及相關的組合物和方法
PH12013500481A1 (en) Estrogen receptor modulators and uses thereof
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
WO2011129549A3 (ko) Ph 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
WO2011083150A3 (en) Obesity small molecules
WO2010085665A3 (en) Targeted delivery system
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX339243B (es) Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
MX356801B (es) Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
GB2496795A (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
WO2010117727A3 (en) Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
MX2013010415A (es) Tratamiento de la atrofia vaginal con nueva indicacion para la mirra.
WO2014066400A3 (en) Methods for the effective treatment of metastatic cancer
MX350868B (es) Medicamentos y metodos para tratar cancer.
UA43757U (ru) Способ лечения синдрома склерополикистозных яичников с гирсутизмом